Hyundai Pharmaceutical Co., Ltd.

As of May 31, 2026, Hyundai Pharmaceutical Co., Ltd. carries a market capitalization of 208.38B, placing it among publicly traded companies globally. Its enterprise value stands at 239.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, Hyundai Pharmaceutical Co., Ltd. has 30.92M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, Hyundai Pharmaceutical Co., Ltd. maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended May 31, 2026.

Over the twelve months ended May 31, 2026, Hyundai Pharmaceutical Co., Ltd. recorded 596.31M in income tax expense.

As of the close on October 23, 2026, Hyundai Pharmaceutical Co., Ltd.'s stock has gained approximately 79.16% over the past 52 weeks. The 50-day moving average sits at 7,816.80, while the 200-day moving average is 8,359.00.

As of May 31, 2026, Hyundai Pharmaceutical Co., Ltd. holds 18.98B in cash and equivalents against 49.91B in total debt, resulting in a net debt position of 41.86B. Total book value stands at 128.05B, with working capital of 44.36B providing operational flexibility.

These figures cover the twelve months ended May 31, 2026.

Hyundai Pharmaceutical Co., Ltd.'s most recent stock split took place on October 20, 2017 with a 414:425 split ratio.